FDA Approved: RINVOQ — Original Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved Rinvoq (upadacitinib) from AbbVie under an Original Application NDA, granting the drug its initial US marketing authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Atopic Dermatitis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• RINVOQ (Upadacitinib)

Snippet

ORIG AP for RINVOQ (UPADACITINIB)